- Home
- GROV vs INKT Comparison
GROV vs INKT Comparison
Compare GROV & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | INKT |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 57.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GROV | INKT |
|---|---|---|
| Price | $1.46 | $10.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.60 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 54.9K | 6.3K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $6.66 |
| 52 Week High | $1.72 | $76.00 |
Technical Indicators
Market Signals| Indicator | GROV | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 38.81 |
| Support Level | $1.42 | $10.77 |
| Resistance Level | $1.46 | $12.78 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 47.83 | 0.00 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.